Indian drug maker, Cipla has announced that it has released the generic version of Hepatitis C drug, Sofosbuvir in India.
The drug will be marketed under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.
The company's product is a generic version of the drug maker Gilead Sciences Inc's Harvoni tablets. Gilead had decided to licence the manufacturing right of the medicine to generic companies to make it accessible in low-income countries soon after its launch in the US.
‘Hepatitis C viral infection affects about 12-18 million in India and 185 million people globally.’
Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients.
Managing Director and Global Chief Executive Officer Subhanu Saxena said, "The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus."